SEARCH

SEARCH BY CITATION

References

  • 1
    Anonymous. The Optimal Duration of Exclusive Breastfeeding. Report of an expert consultation (Document WHO/NHD/01.09). Geneva: World Health Organization 28-30 March 2001. Available online at: http://www.who.int/nut/ (last accessed 14 July 2005).
  • 2
    Klement E, Cohen RV, Boxman J, Joseph A, Reif S. Breastfeeding and risk of inflammatory bowel disease: a systematic review with meta-analysis. Am J Clin Nutr 2004; 80: 134252.
  • 3
    Bennett PN. Drugs and Human Lactation, 2nd edn. Amsterdam: Elsevier 1996.
  • 4
    Armenti VT, Mortiz MJ, Davison JM. Drug safety issues in pregnancy following transplantation and immunosuppression: effects and outcomes. Drug Saf 1998; 19: 21932.
  • 5
    Thiagarajan KD, Easterling T, Davis C, Bond EF. Breast-feeding by a cyclosporine-treated mother. Obst Gynecol 2001; 97: 8168.
  • 6
    Grekas DM, Vasiliou SS, Lazarides AN. Immunosuppressive therapy and breast-feeding after renal transplanation. Nephron 1984; 37: 68.
  • 7
    Nyberg G, Haljamäe U, Frisenette-Fich C, Wennergren M, Kjellmer I. Breast-feeding during treatment with cyclosporine. Transplantation 1998; 65: 2535.
  • 8
    Coulam CB, Moyer TP, Jiang N-S, Zincke H. Breast-feeding after renal transplantation. Transplant Proc 1982; 14: 6059.
  • 9
    Anonymous. Purinethol. [Prescribing information]. Sellersville, PA: Gate Pharmaceuticals. Available online at http://www.fda.gov/cder/foi/label/2004/09053s024lbl.pdf (last accessed 19 July 2005).
  • 10
    Gearry RB, Barclay ML, Roberts RL, Harraway J, Zhang M, Pike LS, George PM, Florkowski CM. TPMT and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Intern Med J 2005; 35: 5805.
  • 11
    Ciulla TA, Sklar RM, Hauser SL. A simple method for DNA purification from peripheral blood. Anal Biochem 1988; 174: 4858.
  • 12
    Roberts RL, Barclay ML, Gearry RB, Kennedy MA. A multiplexed allele-specific polymerase chain reaction assay for the detection of common thiopurine S-methyltransferase (TPMT) mutations. Clin Chim Acta 2004; 341: 4953.
  • 13
    Sies C, Florkowski CM, George PM, Gearry RB, Barclay ML, Harraway J, Pike L, Walmsley T. Measurement of thiopurine methyl transferase activity guides dose-initiation and prevents toxicity from azathioprine. NZ Med J 2005; 118: 1210.
  • 14
    National Center for Health Statistics. Clinical Growth Charts. Available online at http://www.cdc.gov/nchs/data/nhanes/growthcharts/set1clinical/Cj41c017.pdf (last accessed 19 June 2005).
  • 15
    Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, Seidman EG. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 70513.
  • 16
    Schutz E, Gummert J, Mohr FW, Armstrong VW, Oellerich M. Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine? Ther Drug Monit 1996; 18: 22833.
  • 17
    Nygaard U, Toft N, Schmiegelow K. Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clin Pharmacol Ther 2004; 75: 27481.
  • 18
    Derijks LJJ, Gilissen LPL, Engels LGJB, Bos LP, Bus PJ, Lohman JJHM, Curvers WL, Van Deventer SJ, Hommes DW, Hooymans PM. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease. Ther Drug Monit 2004; 26: 3118.
  • 19
    Begg EJ, Duffull SB, Hackett LP, Ilett KF. Studying drugs in human milk: time to unify the approach. J Hum Lact 2002; 18: 32332.